Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Q1 FY2024 Earnings Presentation
35 slides from Natural Capsules's earnings presentation, Aug 10, 2023
Slide 1: Cover letter to BSE on investor presentation
ACCREDITED ISO/IEC 17021 CERTIFICATION BODY Date: 10.08.2023 To Listing Compliance Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Subject: Investor Presentation Dear Sir/ Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Oblig
Slide 2: Investor Presentation August 2023
naturalcapsules.com Investor BSE: 524654 Presentation A U G U S T, 2 0 2 3
Slide 3: Safe Harbor
Safe Harbor INVESTOR PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results
Slide 4: Inside this document
Inside this document INVESTOR PRESENTATION Q U A R T E R LY CO M PA N Y BUSINESS HIGHLIGHTS OVERVIEW C A NVA S NATURAL CAPSULES LIMITED FINANCIAL INVESTMENT S U S TA I N A B I L I T Y PERFORMANCE MERITS | 3
Slide 5: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 6: Quarterly Updates – Q1FY24 (Consolidated)
Quarterly Updates – Q1FY24 (Consolidated) INVESTOR PRESENTATION REVENUES 37.70 cr EBITDA 5.96 cr 0.21% Q-o-Q -11.41% Q-o-Q -14.69% Y-o-Y -34.72% Y-o-Y EBITDA MARGINS 15.81% PAT 1.82 cr -184 BPS Q-o-Q -46.15% Q-o-Q -485 BPS Y-o-Y -65.07% Y-o-Y NATURAL CAPSULES LIMITED EPS ₹ 1.96 -42.86% Q-o-Q -73.62%
Slide 7: Management Commentary
Management Commentary INVESTOR PRESENTATION I am pleased to provide you with an update on our performance in Q1FY24. The operating environment in the pharmaceutical industry continued to remain challenging throughout the quarter. Even amid these challenges, our realisations and volumes remained cons
Slide 8: CAPEX Tracker
CAPEX Tracker INVESTOR PRESENTATION Natural Capsules is geared to make significant capital expenditures in the quarters to come and is on track with its capsule business. The Company will focus on ramping up its endeavours in its API business in the coming quarters. Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q1FY2
Slide 9: Upcoming API Plant
Upcoming API Plant 8 | NATURAL CAPSULES LIMITED INVESTOR PRESENTATION
Slide 10: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) Q1FY23 Q4FY23 Q1FY24 Q-o-Q Y-o-Y Revenues from Operations 44.19 37.62 37.70 0.21% (14.69%) Other Income 0.23 0.21 0.17 (23.53%) (26.09%) Total Income 44.42 37.83 37.87 0.11% (14.75%) Total Operating Expens
Slide 11: Company Overview
naturalcapsules.com Company Overview
Slide 12: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) INVESTOR PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Publ
Slide 13: Our Journey
Our Journey INVESTOR PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION 1993-95 2001 2003 2004 2005-07 2009-12 2012-14 • NCL was • Soon after, in • 2003 was an • The coming • In 2005-2007, NCL • In 2009-2012, • In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acqu
Slide 14: Our Journey (contd.)
Our Journey (contd.) INVESTOR PRESENTATION 2015 – 2018: THE HURDLES WE 2019 ONWARD: THE BEGINNING GOING FORWARD FACED ON THE WAY OF A NEW AND IMPROVED NCL 2015 – 18 2019 ONWARD Installed capacity as at Q4FY23 stands at 18 BCPA • Fall in oil and commodity prices led to economic • 2019 onward NCL witn
Slide 15: Product Offerings
Product Offerings INVESTOR PRESENTATION Natural Capsules Limited manufactures a vast array capsules, including vegetarian capsules which they have pioneered in India. The company in now foraying into API manufacturing with complex CAP S U LE S AP I s high-end patented technology developed in-house,
Slide 16: Global Presence
Global Presence INVESTOR PRESENTATION Natural Capsules exports to 30 countries across 5 continents, bringing in sizable revenue from its export. % OF EXPORT SALES AFRICA CIS • Algeria • Georgia 2.22% • Egypt • Uzbekistan • Ghana • Turkey • Kenya CIS MIDDLE EAST • Nigeria • South Africa • Iran 22.16%
Slide 17: Serving Leading Brands
Serving Leading Brands INVESTOR PRESENTATION With over 3 decades of experience in the pharma sector, NCL has garnered CUSTOMERS FOR MORE THAN excellent relationship with customers across 30 countries. The company is now 10 YEARS focused on acquiring customers who deal with regulated markets. 15% of
Slide 18: Board of Directors
Board of Directors INVESTOR PRESENTATION Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR NATURAL CAPSULES LIMITED Mr. Pramod Kasat Mr. C P Rangachar Mr. S G Belapure Mrs. Jyothi Mundra INDEPE
Slide 19: Business Canvas
naturalcapsules.com Business Canvas
Slide 20: Capsules Segment
Capsules Segment INVESTOR PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, 2nd largest following stringent applicable ru
Slide 21: Enhancing Capacities
Enhancing Capacities INVESTOR PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. CAPSULES MANUFACTURING CAPACITY The ability to deliver faster ₹ 38 Crores planned cap
Slide 22: API Segment
API Segment INVESTOR PRESENTATION Natural Capsules Limited is now foraying into the API business segment through its subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at incorporated in 2020. The APIs that will be manufactured Tumkur, spread across 5 acres are,Hydrocortisone, Pre
Slide 23: API Segment (contd.)
API Segment (contd.) INVESTOR PRESENTATION THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME INR 130 Crores - planned capital expenditure for setting up the facility DEXAMETHASONE 10 MT 11 MT • NCL will be the only manufacturer of this product Planned Capacity Imports to
Slide 24: Production Linked Incentive (PLI) Scheme
Production INVESTOR PRESENTATION Linked Incentive • The scheme intends to boost domestic manufacturing (PLI) Scheme of identified KSMs, Drug Intermediates and APIs by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-
Slide 25: Focus on R&D
Focus on R&D INVESTOR PRESENTATION NCL strongly believes in investing in R&D, to stay ahead of its peers and to consistently innovate. The Company’s recent entry into the API business is 2 DSIR a testament to its firm belief in R&D. Recognised state of the art R&D facilities R&D SPENDS & KEY AREAS O
Slide 26: Sustainability
naturalcapsules.com Sustainability
Slide 27: Sustainability Initiatives
Sustainability INVESTOR PRESENTATION Initiatives • Zero discharge facilities • Solar power generation SUSTAINABLE SITES • Solar concentrated heat generation funded by IREDA and 1st company to receive UNIDO grant for patented solar concentrated heat generation dishes in India NCL believes in • Recycl
Slide 28: Financial Performance
naturalcapsules.com Financial Performance
Slide 29: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY19 FY20 FY21 FY22 FY23 Revenue from Operations 59.78 61.55 79.51 135.07 172.37 Other Income 1.13 0.95 0.73 1.01 0.57 Total Income 60.91 62.50 80.24 136.08 172.94 Total Operating Expenses 54.89 56.25 68.5
Slide 30: Balance Sheet Summary (Consolidated)
Balance Sheet Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY19 FY20 FY21 FY22 FY23 Total Equity (Networth) 55.49 55.62 62.10 82.98 148.25 Non Current Liabilities 1.23 1.08 1.55 34.85 73.57 Current Liabilities 17.61 17.98 33.30 46.45 66.89 Total Equity and Liability 74.33 7
Slide 31: Cash Flow Statement Summary (Consolidated)
Cash Flow Statement Summary (Consolidated) INVESTOR PRESENTATION PARTICULARS (₹ IN CRORES) FY19 FY20 FY21 FY22 FY23 Cash Flow from Operating Activities 2.09 6.90 5.78 1.16 15.53 Cash Flow from Investing Activities (7.06) (5.74) (8.54) (45.88) (104.63) Cash Flow from Financing Activities 4.28 (1.18)
Slide 32: Investment Merits
naturalcapsules.com Investment Merits
Slide 33: Growth Drivers
Growth Drivers INVESTOR PRESENTATION Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal APIs in India, manu
Slide 34: Strategic Priorities
Strategic Priorities INVESTOR PRESENTATION NCL is geared to bring about monumental changes in its approach towards its business. With the ongoing CAPEX, the S T R AT E G I C P R I O R I T Y AC T I O N S TA K E N Company is enabling itself to • Positioning the business to reduce margin • Collaboratin
Slide 35: Thank You
naturalcapsules.com Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Mr. Abhishek Mehra TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynagar II Block, Bangalore - 560 011, IN